Quay Pharmaceuticals has invested in a variety of new equipment as part of its move to its purpose-designed facility in Deeside, U.K., which was officially opened last year.
Pharmatek Laboratories, Inc. has added spray drying to its drug formulation and manufacturing capabilities, purchasing a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture.
ERT has signed three contracts with pharmaceutical companies for its electronic patient reported outcomes (ePRO) business , totaling over $10 million.
DaVita Clinical Research has completed a Phase I-IIa cleanroom to comply with USP 797 high risk regulations demonstrating the cleanroom meets the requirements to handle compounds in a safe and efficient manner.
PPD, Inc. announced it has established four practice areas through PPD Consulting-biosimilars, adaptive trial design, China regulatory strategy, and cardiovascular outcomes studies.
Harman Dubé has joined Ockham as vice-president of pre-clinical and regulatory affairs within the OckhamCRO division.
ERT, appointed Jeffrey S. Litwin, MD as its new president and chief executive officer and as a member of the board.
Kole has joined Almac’s Clinical Technologies business unit as vice president of Clinical Project Services (CPS) and a member of the executive leadership team.
Genentech reported that data showing new personalized approaches for skin and lung cancer patients, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7.
Allon Therapeutics Inc. has updated the progress of a Phase 2/3 clinical trial that is evaluating the company's lead neuroprotective drug candidate, davunetide as a potential treatment for progressive supranuclear palsy (PSP), a rapidly-progressing and fatal degenerative brain disease.
Takeda Pharmaceutical Co. said it will buy Switzerland's Nycomed for $13.6 billion, in an all-cash deal that is the largest ever overseas takeover by a Japanese pharmaceutical company.
inVentiv Health announced it has signed a definitive agreement to purchase PharmaNet Development Group, extending its global presence to nearly 40 countries and enhancing both its early- and late-stage clinical development capabilities.
The QuantiPlasma Array, a monoclonal antibody microarray from Randox Pharma Services, is designed to assess the level of multiple proteins simultaneously in human plasma.
arGEN-X announced that ARGX-110, a human antibody specific for an undisclosed, clinically validated cell surface receptor has moved into formal pre-clinical development, less than 18 months since beginning its operations.